Clopidogrel

Pharmacists are one of the most accessible health care providers and singularly well positioned to lead efforts in integrating pharmacogenomics testing to improve medication-related outcomes.

Extended clopidogrel monotherapy after 9-to-12-month dual antiplatelet therapy reduced risk for adverse events in patients with ACS at increased bleeding and ischemic risk who underwent drug-eluting stent implantation, a speaker reported.

In patients with minor nondisabling acute ischemic stroke, treatment with dual antiplatelet therapy was noninferior to treatment with IV alteplase, according to the results of the ARAMIS trial.

In a new analysis of the pooled cohort of the two STOPDAPT-2 trials of patients who had PCI, clopidogrel monotherapy after 1 month of dual antiplatelet therapy was associated with reduced bleeding risk regardless of diabetes status.

CHICAGO — In patients who had PCI with a drug-eluting stent, dual antiplatelet therapy with indobufen plus clopidogrel was noninferior to DAPT with aspirin plus clopidogrel, according to the results of the OPTION trial.

After a minor stroke or transient ischemic attack, patients with normal vs. impaired renal function treated with ticagrelor plus aspirin had lower risk for stroke at 90 days compared with clopidogrel plus aspirin, researchers reported.

GENEVA — Women who used low-dose aspirin did not exhibit reduced risk for breast cancer, according to study results presented at World Cancer Congress.

The role and status of cannabis in the United States have evolved both medically and legally. In 2020, 49.6 million people in the United States reported using a form of cannabis in the previous year.

Among patients with CAD, P2Y12 monotherapy was superior to aspirin monotherapy for prevention of CV death, MI and stroke, according to an individual patient data meta-analysis presented at the European Society of Cardiology Congress.

Anticoagulation and antiplatelet therapy can reduce risk for venous thromboembolism in COVID-19; however, research suggests these treatments may not influence risk for mortality, speakers reported.